端粒酶在乳癌、乳腺瘤样病变中的表达

Study of Telomerase Activity in Human Breast Cancer

目的 讨论端粒酶在乳癌、乳腺瘤样病变组织中的表达情况及化疗、生长抑素对端粒酶的活性的影响。方法 采用TRAP方法对 88例乳癌及 5 1例乳腺瘤样病变进行端粒酶活性检测。结果 端粒酶在正常乳腺腺体、乳腺纤维瘤中未见表达 ,在乳腺导管上皮轻度不典型增生中为 10 % (1/10 ) ;在乳腺导管上皮中度不典型增生中为 2 0 % (3/15 ) ;在乳腺导管上皮重度不典型增生中为 (75 % ) ;Ⅰ期乳癌中为 90 % (9/10 ) ;Ⅱ期乳癌为 93.1% (2 7/2 9) ;Ⅲ期乳癌为 98% (14 /15 ) ;Ⅲ期乳癌经生长抑素治疗后端粒酶活性下降为 5 5 % (11/2 0 ) ,Ⅳ期乳癌经术前化疗端粒酶活性亦下降 ,为 6 0 % (6 /10 )。结论 端粒酶是一种较好的乳腺肿瘤标记物 ;

Objective To investigate the telomerase activity in human breast cancer and fibroadenoma.To study the the effect of Somatostatin on telomerase activity.Methods Eighty eight cases breast cancer and 85 cases fibroadenoma were study for the presence of telomerase activity by TRAP methods.Results None of the breast fibroadenoma possessed the expression of telomerase activity.The hyperplastic disease of breast expressed telomerase activity expectively in 10%,20%,75%,and telomerase activity of breast cancer in stage Ⅰ,Ⅱ,Ⅲ expectively were 90%,93.1%,98%.Telomerase activity in breast cancer stage Ⅲ,Ⅳ decrease to 55%～60% after usage of the Somatostatin.Conclusion Telomerase activity might be a good marker in breast cancer and Somatostatin may decrease the telomerase activity of breast cancer.